New York State Common Retirement Fund Cuts Holdings in Inogen, Inc (INGN)

New York State Common Retirement Fund lowered its position in shares of Inogen, Inc (NASDAQ:INGN) by 0.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 385,741 shares of the medical technology company’s stock after selling 3,465 shares during the quarter. New York State Common Retirement Fund owned about 1.86% of Inogen worth $36,684,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Inogen by 1.9% during the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock valued at $205,207,000 after purchasing an additional 39,752 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Inogen by 24.9% during the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares during the last quarter. Koch Industries Inc. grew its holdings in shares of Inogen by 19,485.8% during the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Inogen by 3.4% during the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after purchasing an additional 17,111 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Inogen by 6.8% during the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after purchasing an additional 27,250 shares during the last quarter.

In related news, Director Heath Lukatch sold 2,500 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $126.40, for a total value of $316,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $102.30, for a total value of $1,432,200.00. Following the completion of the transaction, the director now directly owns 7,808 shares of the company’s stock, valued at $798,758.40. The disclosure for this sale can be found here. Insiders sold a total of 88,000 shares of company stock valued at $9,349,730 over the last three months. Corporate insiders own 5.31% of the company’s stock.

Several equities analysts have recently commented on the company. Leerink Swann reaffirmed an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. BidaskClub lowered Inogen from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a report on Thursday, November 9th. Needham & Company LLC upped their target price on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $103.14.

Inogen, Inc (NASDAQ INGN) opened at $118.21 on Friday. Inogen, Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05. The stock has a market capitalization of $2,460.00, a P/E ratio of 95.47, a P/E/G ratio of 4.93 and a beta of 1.13.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same period in the prior year, the company posted $0.25 EPS. The business’s revenue for the quarter was up 26.8% compared to the same quarter last year. sell-side analysts anticipate that Inogen, Inc will post 1.19 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “New York State Common Retirement Fund Cuts Holdings in Inogen, Inc (INGN)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/09/new-york-state-common-retirement-fund-cuts-holdings-in-inogen-inc-ingn.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply